Results

Total Results: 1,636 records

Showing results for "treating".

121. Functional-Limitations-Horizon-Scan-High-Impact-1306 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/functional-limitations-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - Food and Drug Administration (FDA) approved dimethyl fumarate in February 2013 for treating adults … Two other orally administered MS drugs, teriflunomide (approved for treating RRMS) and laquinimod, … Argus II is the first implanted device FDA approved for marketing for treating adult patients with … The indication is for treating adult patients with relapsing forms of MS.16 Diffusion: A query of … Argus II is the first FDA-approved, implanted device for treating adults with advanced RP.

122. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1506.pdf
     November 01, 2016 - spontaneous preterm birth, interventions intended to target both the pregnant woman and fetus (a drug for treating … preeclampsia, another for preventing preterm birth, and a weight-management program), and a program for treating … Elagolix is a new, oral, fast-acting, nonpeptide GnRH receptor antagonist for treating endometriosis … may be indicated.1 Elagolix is a new, oral, fast-acting, nonpeptide GnRH receptor antagonist for treating

123. Updating Current Effectiveness Reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-assessment-research-updates_research.pdf
     September 15, 2008 - burden of illness; evidence suggesting underuse or overuse; the cost of the intervention or of not treating … Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating … Angiotensin- Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating … Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating

124. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypothyroidism-hyperthyroidism-screening-treatment_executive.pdf
     October 01, 2011 - Therefore, it has been proposed that screening for and treating subclinical thyroid dysfunction might … screening and treatment of subclinical thyroid dysfunction, primarily based on the lack of evidence that treating … receiving an initial set of Key Questions and an analytic framework for the process of screening and treating … a readily available, reliable, and acceptable test.1 However, in 2004, it remained unclear whether treating

125. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1512.pdf
     November 01, 2016 - in preterm infants, interventions intended to target both the pregnant woman and fetus (a drug for treating … preeclampsia, another for preventing preterm birth, and a weight-management program), and a program for treating … Elagolix is a new, oral, fast-acting, nonpeptide GnRH receptor antagonist for treating endometriosis … indicated.1 Elagolix is a new, oral, fast-acting, nonpeptide GnRH receptor antagonist in development for treating

126. Management of Renal Masses and Localized Renal Cell Carcinoma: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-cancer_clinician.pdf
     July 01, 2017 - evaluated the recent evidence regarding the benefits and adverse effects of strategies for evaluating and treating … Surgical removal (either partial or radical nephrectomy) is the gold standard for treating renal cell … sought to determine the effectiveness and comparative effectiveness of strategies for evaluating and treating

127. Cancer-Anemia-Update Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia-update_executive.pdf
     April 01, 2013 - Transfusion is one option for treating anemia related to cancer and cancer treatment. … Health-Related Quality of Life Treating to high target hemoglobin levels (greater than 12 g/dL) was

128. Therapies for Clinically Localized Prostate Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-update_clinician.pdf
     January 01, 2016 - treatments –� The patient’s and/or caregiver’s values and preferences Companion Resource for Patients Treating … talk with their health care professionals about the various treatment options that are available for treating

129. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/ace-inhibitor-arb-future/research

130. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
     September 26, 2014 - Food and Drug Administration (FDA) approved exenatide extended-release in January 2012 for treating … FDA approved ranibizumab in August 2012 for treating patients with diabetic macular edema. … However, long-term, these procedures could reduce the burden of treating diabetes if they prove safe … Once such injected agent is ranibizumab, which FDA approved in 2012 for treating DME; it purportedly … Intervention: Iluvien is a sustained-release, intravitreal corticosteroid insert intended for treating

131. What is the effectiveness of interventions intended to treat anxiety disorders in children (
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-is-the-effectiveness-of-interventions-intended-to-treat-anxiety-disorders-in-children-18-years-of-age-over-the-long-term-6-12-months-what-is-the-effectiveness-of-interventions-intended-to-prevent-the-development-of-anxi

132. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-13121.pdf
     December 05, 2013 - joint cartilage and restore function, it would have a major impact on patient outcomes and costs of treating … , concentrated, cultured, and expanded in vitro and returned to the patient with the intention of treating … injections of adipose-derived autologous MSC combined with PRP, after arthroscopic débridement, for treating … In terms of patient management, experts were divided on the role MSC therapy may play in treating OA … symptoms of the disease.65 PRP has been used in a number of hemostatic applications as well as for treating

133. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/14_substance_abuse_potential_high_impact_2012-12-11.pdf
     January 01, 2012 - One long-acting version of currently used pharmacotherapy (buprenorphine) has been developed for treating … were successful in improving smoking-cessation rates, some of the long-term costs associated with treating … version of currently used pharmacotherapy (buprenorphine [Probuphine ™ ]) has been developed for treating … Administration (FDA)-approved in other formulations (i.e., sublingual tablet, film formulations) for treating … proposed intervention are sound, based on the historical success of other buprenorphine formulations in treating

134. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/01_arthritis_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - and high out-of-pocket costs for patients are expected to temper the impact of MSC therapy for treating … joint cartilage and restores function, its impact would be major on patient outcomes and costs of treating … Food and Drug Administration approved in November 2012 for treating adults with moderately to severely … Overall, experts were divided on the impact that MSC therapy may play in treating OA. … clinicians can recommend surgery, including joint replacement. 15 If proven to be effective for treating

135. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1406.pdf
     June 01, 2014 - joint cartilage and restore function, it would have a major impact on patient outcomes and costs of treating … , concentrated, cultured, and expanded in vitro and returned to the patient with the intention of treating … injections of adipose-derived autologous MSC combined with PRP after arthroscopic débridement, for treating … therapy and its implementation in specialty centers are more likely to create health disparities in treating … symptoms of the disease.37 PRP has been used in a number of hemostatic applications as well as for treating

136. Topic 0590 Strategies to Treat and Manage Infantile Hemangioma NSD FINAL_SJ (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0715-140408.pdf
     May 29, 2025 - Topic 0590 Strategies to Treat and Manage Infantile Hemangioma NSD FINAL_SJ Strategies to Treat and Manage Infantile Hemangioma Nomination Summary Document …

137. Politi (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/politi.pdf
     May 29, 2025 - Slide  24: Avenues for Future  Research • Who manages the decisions when there are multiple treating

138. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/04_dementia_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - Currently, the beta-amyloid antibody drug class is being investigated for treating AD. … Treatment of Alzheimer’s Disease  Key Facts: Insulin delivered intranasally is being investigated for treating … Because insulin is not approved for treating AD, its use for AD is considered off label. … Therefore, an unmet need exists for novel, effective, potentially disease- modifying agents for treating … research organizations have been begun investigating the use of intranasally delivered insulin for treating

139. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/heart-disease-ace-inhibitor-arb/research

140. Disposition of Comments: CER 228, Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
     April 16, 2020 - type, dosage, and duration of any pain treatment, including opioid therapy, is best determined by the treating … the evidence in this report does not support these CDC recommendations as a viable alternative to treating … Public Reviewer 2 Tom Supinka, National Safety Council Question 9 Given the complexity of treating … Best Practices Task Force, which focus on an integrative, multimodal, interdisciplinary approach to treating